Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures. Preotact is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA)."""@en ; dct:identifier "drugbank:DB05829" ; dct:title "Preotact"@en ; adv:Drug ; rdfs:label "Preotact [drugbank:DB05829]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05829> . }